Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Royal Marsden NHS Foundation Trust |
---|---|
Information provided by: | Royal Marsden NHS Foundation Trust |
ClinicalTrials.gov Identifier: | NCT00220103 |
To investigate the efficacy and safety of epirubicin, cisplatin and capecitabine as neoadjuvant therapy prior to radical resection in patients with newly diagnosed operable oesophageal adenocarcinoma.
Condition | Intervention | Phase |
---|---|---|
Adenocarcinoma of Oesophagus |
Drug: epirubicin, capecitabine, cisplatin Procedure: Surgical resection |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Pre-Operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma |
Estimated Enrollment: | 80 |
Study Start Date: | November 2002 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Patients with disease in any of the following areas on the basis of CT scan and/or endoscopic ultrasound:
Contact: David Cunningham | 0208 661 3156 |
United Kingdom, Surrey | |
Royal Marsden NHS Foundation Trust | Recruiting |
Sutton, Surrey, United Kingdom | |
Contact: David Cunningham 0208 661 3156 | |
Principal Investigator: David Cunninham |
Principal Investigator: | David Cunningham | Royal Marsden NHS Foundation Trust |
Study ID Numbers: | 2185 |
Study First Received: | September 19, 2005 |
Last Updated: | May 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00220103 History of Changes |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Antimetabolites Anti-Bacterial Agents Capecitabine Radiation-Sensitizing Agents Cisplatin Esophageal Disorder |
Esophageal Diseases Adenocarcinoma Epirubicin Neoplasms, Glandular and Epithelial Carcinoma |
Antimetabolites Capecitabine Antimetabolites, Antineoplastic Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Antibiotics, Antineoplastic Epirubicin |
Pharmacologic Actions Carcinoma Neoplasms Cisplatin Radiation-Sensitizing Agents Therapeutic Uses Adenocarcinoma Neoplasms, Glandular and Epithelial |